Kornimate/medical-research-clean huggingface dataset:
depression management at the workplace

Conditions: Depression

Summary: randomized trials demonstrate that depression management products can improve clinical and organizational outcomes sufficiently for selected employers to realize a return on investment. rather than usual care marketing which uses voltage-enhanced promises to sell voltage-diminished products, the investigators designed an evidence-based (eb) intervention to encourage employers to purchase a depression management product that offers the type, intensity and duration of care shown to provide clinical and organizational value. in an rct designed to examine employer benefit purchasing behavior of depression products in 360 employer members of over 20 regional business coalitions, the research team proposes: (a) to compare the impact of evidence-based (eb) to usual care (uc) presentations on employer benefit purchasing behavior, and (b) to identify mediators and organizational moderators of intervention impact on employer benefit purchasing behavior. this study addresses what policy analysts argue is one of the most pivotal problems in the translation of evidence-based care to 'real world' settings: whether purchasers can be influenced to buy health care products on the basis of value rather than cost. in the likely event that eb \> uc, the study will provide encouragement to use an evidence-based approach to market new health care products to private payers on the basis of the product's clinical and organizational value. uc may achieve comparable outcomes to eb if the limiting factors in benefit purchasing are organizational, purchasing group and vendor constraints that no intervention can meaningfully modify. support for this scenario would encourage the targeted marketing of new products to coalition members with empirically identified organizational, purchasing group and vendor characteristics, using usual care strategies.


Eligibility criteria:
inclusion criteria: * coalitions who belong to the national business coalition on health are eligible if: * they have 30+ employer purchasers/affiliates as members * they act as more than purchasing agents * (3)they did not participate in the research team's preliminary studies on this topic. * employers of participating coalitions are eligible if: * they are a public or private organization providing health care benefits to 100+ domestic employees * they have not purchased a depression management product in the past two years. exclusion criteria: * none

Keywords: depression depression care management financing absenteeism presenteeism employer decisions to purchase health care benefits
study of d3s-002 as monotherapy in adult subjects with advanced solid tumors with mapk pathway mutations

Conditions: Advanced Solid Tumors With MAPK Pathway Mutations

Summary: this first-in-human (fih) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (rp2d) of d3s-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (mapk) pathway mutations.


Eligibility criteria:
inclusion: * subjects must have a histologically or cytologically confirmed metastatic or locally advanced solid tumor with evidence of progressive disease. * subjects must have documented mitogen-activated protein kinase (mapk) pathway mutation(s) within the last 5 years identified by a local test on tumor tissue or blood (eg, rat sarcoma (ras), rapidly accelerated fibrosarcoma (raf), and mapk kinase (mapkk) mutations). * subjects must be refractory to or intolerable with standard treatment, or have no available standard of care. * subject must have eastern cooperative oncology group (ecog) performance status of 0 to 1. * subject must have adequate organ and marrow function within the screening period. exclusion: * subject has any prior treatment with other treatments without adequate washout periods as defined in the protocol. * subject has uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring aes, or compromise the ability of the subject to give written informed consent. * subject has unresolved treatment-related toxicities from previous anticancer therapy of nci ctcae grade ≥2 (with exception of vitiligo or alopecia). * subject has active gastrointestinal disease or other that could interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy. * any concurrent chemotherapy, immunotherapy, targeted therapy, cell therapy, biologic or hormonal therapy and any medical devices for cancer treatment.

Keywords: advanced solid tumors mitogen-activated protein kinase mutation
comparison of different methods of enamel preparation before pit and fissure sealants

Conditions: Enamel Lesions; Dental Caries

Summary: this study concerns the prevention of dental caries by sealing pits and fissures of permanent molars with a photopolymerizable resin. it must compare these three techniques microdentisty (air abrasion, abrasion and sound using small cutters) usually used to prepare micro cavities in the enamel and / or the outer third of the dentin. these three commonly used techniques have never been compared by retaining as endpoint retention of sealant. these techniques are painless and do not require local anesthesia.


Eligibility criteria:
inclusion criteria: * affiliated with the social security * attendance at inspections * subject to high individual risk of caries * subjects with at least two pairs of molars and contralateral counterparts with the initial lesions of enamel (pits and fissures colored) or suspected of dentine caries (not highlighted by two clinical and radiographic examination usual) exclusion criteria: * molar inaccessible, closed, sealed, or decayed (reaching the dentine

Keywords: suspected caries initial enamel lesions
indinavir plus efavirenz plus adefovir dipivoxil in hiv-infected patients who have not had success with nelfinavir

Conditions: HIV Infections

Summary: the purpose of this study is to compare the effectiveness of giving indinavir plus efavirenz plus adefovir dipivoxil to patients who have failed treatment with nelfinavir and patients who have never taken a protease inhibitor (pi). effectiveness is measured by the number of patients who have a viral load (level of hiv in the blood) below 400 copies/ml after 48 weeks of treatment.

in this open-label, nonrandomized study, 120 hiv-infected patients are stratified into two groups: failed nelfinavir vs protease inhibitor-naive. all patients receive indinavir plus efavirenz plus adefovir dipivoxil plus and l-carnitine, orally. plasma vrna is measured every 4 weeks until week 16, then every 8 weeks for the remainder of the 48-week study.

Eligibility criteria:
inclusion criteria patients must have: * serologically documented hiv infection. * baseline cd4 count greater than or equal to 50 cells and vrna greater than or equal to 10,000 copies/ml. * parental consent for patients under 18. nelfinavir-failure group: * must have protease inhibitor experience solely with nelfinavir and be considered drug-adherent. * must be candidate for changing therapy because of virologic failure and be receiving nelfinavir at entry (at least 16 weeks of nelfinavir plus nrti therapy with at least a 10-fold decline in vrna due to nelfinavir therapy and a subsequent increase toward the patient's baseline vrna of at least 10-fold). control group: * must have received any combination of currently licensed nucleoside reverse transcriptase inhibitors for at least 16 weeks. * must be naive to efavirenz, adefovir dipivoxil, and other nrti's. exclusion criteria prior medication: excluded: control group: * prior efavirenz, adefovir dipivoxil, or other non-nucleoside reverse transcriptase inhibitors. required: nelfinavir-failure patients: * at least 16 weeks of nelfinavir. control group: * at least 16 weeks of any combination of currently licensed nucleoside reverse transcriptase inhibitors.

Keywords: drug resistance drug therapy, combination antiviral agents hiv protease inhibitors indinavir rna, viral adenine efavirenz
the study on nutritional status of patients with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: the global aging population is rising year by year. according to the result of taiwan epidemiological survey, dementia has become the health issue in aging population. mild cognitive function impairment may present years before dementia is diagnosed. therefore early diagnosis of dementia at its mild cognitive function impairment stage is beneficial for disease prevention and potentially delaying the deterioration of cognitive function impairment. nutritional status includes a healthy diet, favor body composition and activity habits, which not only reduces the risk of nutritional metabolic diseases, but also has a direct relationship with delaying cognitive function impairment. the dietary quality index of mediterranean-dietary approaches to stop hypertension intervention for neurodegenerative delay diet (mind diet) may prevent aging and positively associated with delaying dementia in elderly. however, the result in dietary quality index and delaying cognitive function impairment from current studies were still unclear. in additions, based on the differences in dietary patterns between taiwan and western countries, no current calorie and dietary nutrition recommendations. this cross-sectional study is to investigate the association between dietary quality index and nutritional status risk factors in cognitive function impairment patients and expected to develop an assessment tool for taiwanese clinical nutrition strategies and applications.

aging populations is rising by years in taiwan. mild cognitive function impairment (mci) has become the important health issue. current knowledge of the etiology of cognitive decline is incomplete, the potential modifiable factors, such as diet may delay the deterioration of disease. this study is aimed to comprise the differences nutritional status,include dietary nutrients intake, mind diet scores,body composition analysisin with mild cognitive impairment. design and methods: this cross-sectional study from july, 2019. according to clinical dementia rating (cdr) and mini-mental state examination (mmse), subjects are divided into healthy group (cdr = 0 and mmse ≧ 26) and mci group (cdr ≧ 0.5 and mmse ≧ 26). dietary data were obtained by 3-day dietary records and nutrients intake were calculated by trained dietitian. we expected to understand the nutritional status of patients with mild cognitive impairment.

Eligibility criteria:
inclusion criteria: 1. age ≥40 years old (regardless of gender) 2. complete 3-day dietary record, mini-mental state examination and clinical dementia rating assessment 3. independent physical activity exclusion criteria: 1. no amputation, edema, cancer, terminal case, thyroid disease and stroke include stroke history 2. no family support 3. psychological problem 4. extremely data of dietary record(\ 3500 kcal)
comparison of inflight first aid performed by cabin crew members and medical volunteers

Conditions: Emergency

Summary: since the number of air travelers, including the elderly and passengers with an underlying disease, is increasing every year, the number of inflight emergency patients is expected to increase as well. the investigators attempted to identify the incidence and types of inflight medical emergencies and analyze the first aid performed by cabin crew members or medical volunteers in flights by an asian airline. the investigators also investigated the causes of inflight deaths and aircraft diversions.


Eligibility criteria:
inclusion criteria: * inflight medical emergencies from 2009 to 2013 exclusion criteria: * events that occurred before takeoff or after landing

Keywords: aircraft emergency first aid cabin crew burn cardiac arrest
investigating the anti-human immunodeficiency virus (hiv) & anti-inflammatory effect of chloroquine

Conditions: HIV Infections

Summary: summary: chloroquine is a medication that in laboratory settings has significant anti-hiv effects in hiv infected t-cells. chloroquine has been used safely for over 60 years for malaria treatment and prevention, and it also has significant anti-inflammatory effects. no formal study of chloroquine has been performed in people with hiv infection. chloroquine is used worldwide and is quite inexpensive outside of the united states. if shown to be effective, chloroquine could be a very important tool worldwide in delaying hiv disease progression which would extend the time period without needing anti-retroviral therapy. in countries where anti-retroviral therapy is not available, this could be very helpful. this is an 8 week trial study requiring 3 study visits. participants will be ask to take a once a day study medication (chloroquine or placebo) for 8 weeks and have three blood draws for cd4 counts, hiv viral loads, and other research tests. the visits are at study enrollment, 4 weeks, and 8 weeks.

summary: a phase i randomized, double-blind, placebo controlled trial to investigate the efficacy of chloroquine to decrease t-cell activation and decrease viral load in early hiv. scientific rationale: chloroquine has in vivo direct anti-hiv effects and an anti-inflammatory effect. these properties may be beneficial in reducing viral burden and immune activation therefore delaying hiv disease progression. sample size: 25 length of study: 8 weeks, \[enrollment + 2 follow up visits\]. intervention: * arm 1a: chloroquine 250mg orally once daily for 8 weeks. * arm 1b: chloroquine 500mg orally once daily for 8 weeks. * arm 2: placebo once daily for 8 weeks. measurements: * blood draws at weeks: 0, 4, and 8 weeks. * cd4, viral load measurements will be communicated to the referring provider (with subject consent).

Eligibility criteria:
inclusion criteria: * hiv-1 infected adults * cd4 count \> 250 cells/mm3 * not presently receiving hiv antiretroviral therapy (\> 6 months or naïve) * viral load \> 3000 rna copies/ml (3.5 log) * no planned hiv anti-retroviral therapy for 8 weeks exclusion criteria: * prior retinal eye disease * cd4 \< 250 cells/µl * renal failure * active malignancy * corticosteroid therapy * age \ 65 years

Keywords: hiv chloroquine disease progression inflammation treatment naive
x-396 (ensartinib) capsules in alk-positive nsclc patients with brain metastases

Conditions: Lung Cancer, Nonsmall Cell; Brain Metastases

Summary: to assess efficacy and safety of oral x-396 (ensartinib) capsule in chinese alk-positive nsclc patients with brain metastases, eligible patients will be enrolled with objective responses being primary outcome measures.

in this phase ⅱ, open-label, single arm, multicenter study, efficacy and safety of oral x-396 capsule (ensartinib) in 37 chinese alk-positive nsclc patients with brain metastases will be assessed. eligible patients will receive 225mg x-396 capsules once daily and objective responses of brain metastasis based on investigator assessment according to response assessment in neuro-oncology (rano) are primary outcome measures.

Eligibility criteria:
inclusion criteria: 1. female or male, 18 years of age or older 2. histologically or cytologically confirmed locally advance or recurrent/metastatic nsclc that was positive for alk mutations. 3. contrast-enhanced mri or ct confirmed parenchymal brain metastases with at least one measurable lesion (according to rano and recist 1.1), which was not previously treated with radiotherapy. 4. at most once treated with chemotherapy, which must have been completed at least 4 weeks before the initiation of study treatment. any adverse events related to previous chemotherapy treatment have disappeared. 5. a karnofsky performance status score of at least 60. 6. an expected survival time of at least 12 weeks. 7. adequate organ functions. 8. drug related toxicities has been relieved to grade 1 (based on nci ctcae v4.03), except for hair loss. 9. being willing and able to comply with scheduled visits, treatment plans, laboratory tests and other study procedures. 10. signed and dated informed consent. exclusion criteria: 1. currently under treatment of other systemic anti-cancer therapies. 2. evidence of active malignancy within last 5 years. 3. patients who participated in other clinical trials within last 4 weeks before the initiation of study treatment. 4. patients who received surgery or immunotherapy within last 4 weeks before the initiation of study treatment. 5. patients who need to receive drugs which are potent cyp3a4 inhibitors or inducers within last 2 weeks before the initiation of study treatment and during the study. 6. patients who previously received organ transplantation or stem cell transplantation. 7. patients with clinically significant cardiovascular diseases. 8. patients with active gastrointestinal diseases or other conditions that will interfere significantly with the absorption, distribution, metabolism or excretion of study medication. 9. patients with interstitial lung disease history or signs of active interstitial lung disease. 10. patients with known allergy or delayed hypersensitivity reaction to study drug or its excipients. 11. pregnant and lactating women. 12. patients with other illness or medical conditions potentially interfering with the study treatment.

Keywords: nsclc, brain metastases, alk mutations, x-396 (ensartinib)
effect of a healthy food voucher on blood glucose control in people with type 2 diabetes or prediabetes

Conditions: Diabete Type 2

Summary: this randomized controlled trial (rct) will determine if access to a voucher for healthy foods reduces blood sugar levels among people living on a low income who have type 2 diabetes or elevated blood sugar.


Eligibility criteria:
inclusion criteria: * hemoglobin a1c 6.0 to 11.0 * report food insecurity or financial insecurity exclusion criteria: * live with a current study participant * life expectancy \< 6 months * multiple life-threatening allergies to common foods * require total parenteral nutrion * blood dyscrasia that interferes with hemoglobin a1c interpretation * hemoglobin a1c \>11
comet india follow-up trial

Conditions: Depressive Symptoms; Anxiety; Happiness

Summary: we are evaluating an online single-session intervention for mental health promotion among indian college students.


Eligibility criteria:
inclusion criteria: * college student * access to internet * proficient in english exclusion criteria: -
ultrasound guided erector spinae plane block in breast surgery

Conditions: Postoperative Pain

Summary: hyalorounidase will be added to local anaesthetics in patients undergoing mastectomy and effect on local anaesthetic spread will be studied under floroscope

two groups will be enrolled the control group will receive local anaethetic only and the spread will be observed by floroscope. the seconed group, hyaloronidase will be added to local anaesthetics and the spread will be studied under image.

Eligibility criteria:
inclusion criteria: 1. female 2. asa i, ii, iii 3. elective surgery exclusion criteria: 1. patient refusal 2. infection at injection site 3. allergy to the given drugs
validation study of the simplified seizure classification algorithm

Conditions: Epilepsy

Summary: an algorithm has been developed for simplified classification of epileptic seizures, in order to optimize choice of antiepileptic drugs. the objective of this study was to clinically validate the algorithm.

optimal choice of antiepileptic drugs (aeds) depend on the patients´ seizure-types. over the last four decades, several classification systems have been proposed for epileptic seizures. the recent position paper of the international league against epilepsy defines 63 seizure-types. while this complex system might be useful for detailed phenotyping, currently there is no evidence that each of these seizure-types needs different clinical management strategy, and many clinicians find it difficult to implement. to help physicians with optimizing the choice of aeds, the investigators developed a simplified seizure classification, consisting of the minimal number of seizure-types, necessary for choice of aeds, and the investigators developed an algorithm that identifies the patient´s seizure-type, based on a set of 10 simple questions, that can be answered by physicians even without extensive training in epilepsy. the current form of the algorithm was developed for patients whose seizures started in adolescence or adulthood (at the age of 10 years or older). in this study, the investigators aim to validate the diagnostic algorithm, by comparing the seizure-type identified by the algorithm with the diagnosis and seizure-type as defined by trained experts, in the clinical workup of the patients.

Eligibility criteria:
inclusion criteria: * patients referred to the participating centers on suspicion of epilepsy exclusion criteria: * none
combined and simultaneous approach for the treatment of high-risk gastric varices using b-rto and evo

Conditions: Gastric Varices Bleeding; Gastric Varix

Summary: the aim of this pilot study is to evaluate the efficacy and safety of combined and simultaneous endoscopic variceal obliteration together with balloon occluded-retrograde transvenous obliteration (b-rto) for the treatment of high-risk gastric varices

although less frequent than esophageal varices, gastric varices constitute a severe and potentially life threatening complication of portal hypertension. various methods have been described to treat gastric varices, including endoscopic and interventional radiology techniques. endoscopic variceal obliteration (evo) is currently considered as standard of care for the treatment of gastric varices in most centers. however, this technique is associated with significant rebleeding rates and incomplete obliteration is observed in about 50% of patients. alternatively, few centers also use an interventional radiology technique, called balloon-occluded retrograde transvenous obliteration (b-rto) to treat gastric varices, which has been shown to be associated with less recurrence of gastric varices and high rates of eradication of about 90%. both techniques have their inherent weaknesses, such as frequent incomplete eradication of varices and thromboembolic events for evo, while data suggest that b-rto may aggravate esophageal varices. the aim of this pilot study is to evaluate the efficacy and safety of combined and simultaneous endoscopic variceal obliteration together with (modified) b-rto. stopping the outflow of gastric varices by endovascular balloon occlusion may allow better endoscopic visualization, blood stagnation and thus eradication of varices, while preventing thromboembolic events. furthermore, during study follow-up, the eradication rates and recurrence of varices, short-term and long term complications, effects of the procedure on portal pressures/hemodynamics and liver function will be evaluated.

Eligibility criteria:
inclusion criteria: 1. informed consent as documented by signature (appendix "fiche d'information aux patients et formulaire de consentement éclairé") 2. patients with endoscopically proven high-risk (diameter \>2 cm, mosaic gastropathy, red spots or signs of previous bleeding) and gov2, igv1 and igv2 type of gastric varices (according to sarin classification) 3. portal hypertension secondary to cirrhosis 4. age \>18 exclusion criteria: 1. acute gastric or esophageal varice bleeding 2. gov1 varices according to sarin classification 3. hemodynamic instability 4. uncompensated cirrhosis 5. contraindication to general anesthesia 6. contraindication to ct-scan/angiography (impaired kidney function, allergy to iodine based contrast) 7. allergy to cyanoacrylate, drugs or material used during procedures 8. absence of gastro-renal shunt 9. pregnancy 10. participation to another study involving ionizing radiation (dose superior to 5msv) without direct benefice for patient during the 12 last months